Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,363.00+0.15%ETH$2,534.95+2.99%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
ZL

NASDAQ · ZLAB

Zai Lab Limited

Healthcare · Biotechnology

$24.17

Down-$0.03 (-0.12%)

Updated Sep 11, 2026, 8:44 PM

SID Score

5.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.97B
P/E ratio
-9.41
Dividend yield
0.00%
52-week range
$15.96 – $34.72
Volume
1.61M
Avg. volume
828.59K

Price performance

ZLAB price history

1M range · 20 trading sessions · Daily adjusted prices

ZLAB closed at $24.17 after 20 trading sessions, down 7.15% for the selected period.

Last close
$24.17
Period change
-7.15%
Period low
$24.17
Period high
$27.00
Daily close
View OHLC price history
ZLAB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$24.01$24.66$23.64$24.171.61M
Sep 9, 2026$25.45$25.57$25.05$25.08491.7K
Sep 8, 2026$25.74$26.50$25.37$25.41711.75K
Sep 4, 2026$26.48$26.49$25.46$26.23812.77K
Sep 3, 2026$26.85$27.135$26.32$27.00585.71K
Sep 2, 2026$26.00$27.50$26.00$26.481.06M
Sep 1, 2026$25.055$25.565$24.81$25.30979.94K
Aug 31, 2026$25.50$25.55$24.87$25.46920.15K
Aug 28, 2026$26.45$26.45$25.8677$26.08650.04K
Aug 27, 2026$27.12$27.20$26.575$26.82597.33K
Aug 26, 2026$25.77$26.18$25.545$26.031.14M
Aug 25, 2026$26.04$26.75$25.905$26.17705.45K
Aug 24, 2026$25.43$25.96$25.25$25.641.15M
Aug 21, 2026$26.25$26.29$25.7234$26.011M
Aug 20, 2026$26.57$26.62$25.92$26.021.39M
Aug 19, 2026$25.82$27.50$25.82$26.721.73M
Aug 18, 2026$24.86$25.62$24.64$25.571.63M
Aug 17, 2026$25.25$25.92$24.77$25.641.36M
Aug 14, 2026$25.44$26.26$25.33$25.901.23M
Aug 13, 2026$26.21$26.382$25.70$26.031.04M

Latest ZLAB news

The latest Smart Investors Daily articles mentioning ZLAB.

Stock researchCompany · Overview

ZLAB research

Overview

Company profile and research snapshot.

Company profile

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$75.00
Implied upside
—
Analysts
—
ZLAB recent ratings
DateFirmRatingTarget
Sep 10, 2020SVB LeerinkOutperform—
Dec 30, 2019CitigroupBuy—
Sep 4, 2019China RenaissanceBuy—
Jul 5, 2019MacquarieOutperform—
Jan 29, 2019Credit SuisseOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 6, 2026

Zai Lab (ZLAB) Stock Looks Stretched On Sales But Reasonable On Broader Checks

Zai Lab stock presents a challenging valuation picture for investors, with a share price that has risen in the shorter term but sits against a five year record of heavy value loss and only a mixed read from broader valuation checks. The share price has fallen 80.9% over the past five years, which points to a significant destruction of shareholder value over a full market cycle. Future revenue growth from its biopharmaceutical portfolio can support the current valuation, while ongoing...

Yahoo · Aug 20, 2026

Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)?

Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) and argenx SE (NASDAQ:ARGX) announced positive topline results on August 17 from their Phase 3 ALKIVIA study evaluating VYVGART Hytrulo in adults with autoimmune myositis. In the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population, patients treated with efgartigimod achieved a statistically significant, 15.4-point greater improvement in […]

Yahoo · Aug 20, 2026

Global DLL3 Targeted Therapies Market 2026-2030: Profiles Amgen, Zai Lab, Boehringer Ingelheim and Phanes Therapeutics

Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) -- The "Global DLL3 Targeted Therapies Market Opportunity, Approved Therapy Sales, Pricing, Proprietary Development Platforms & Clinical Trials Insight 2030" has been added to ResearchAndMarkets.com's offering. Key Report Highlights: Global DLL3 targeted therapies market opportunity projected to exceed USD 2 billion by 2030Analysis of current market trends, growth drivers and future commercial opportunitiesUnited States expected to dominate market sales, wh

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By